OLUX Foam is a super-high-potency topical corticosteroid; therefore, limit treatment to 2 consecutive weeks. Patients should not use greater than 50 grams per week or more than 21 capfuls per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis ...
Stiefel Laboratories recently announced that the FDA has approved Olux-E[TM] (clobetasol propionate) Foam, 0.05% for the treatment of psoriasis and eczema in patients 12 years of age and older. The medication is expected to be available by prescription from pharmacies in the US by March 2007....
McNamara, DamianPediatric News
Olux-E - Detailed Prescribing InformationDrugs
FDA approves Olux-E Foam.(PIPELINE PREVIEWS)(Brief article)Heller, Marissa